Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression

被引:0
|
作者
Horani, Malek [1 ]
Abdel-Razeq, Hikmat [1 ,2 ]
机构
[1] King Hussein Canc Ctr, Dept Internal Med, Amman, Jordan
[2] Univ Jordan, Sch Med, Amman, Jordan
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
CDK4/6; inhibitors; palbociclib; ribociclib; abemaciclib; metastatic breast cancer; disease progression; endocrine therapy; THERAPY; PLUS; PALBOCICLIB;
D O I
10.3389/fonc.2023.1272602
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is the most commonly diagnosed cancer in women worldwide. Over the past decade, the treatment paradigm for patients with metastatic breast cancer (MBC) has taken an important shift towards better survival and improved quality of life (QOL), especially for those with hormone receptor (HR)-positive diseases which represent the majority of breast cancer subtypes. The introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in the upfront therapy of such patients has resulted in dramatic improvement in progression-free survival (PFS) and overall survival (OS), too. However, almost all patients would, sooner or later, develop disease progression and necessitate transition to different lines of treatment that may include chemotherapy. The idea of maintaining CDK4/6 inhibitors beyond disease progression seems attractive, as this approach has the potential to improve outcome in this setting despite the fact that the true benefit, in terms of survival, might not carry the same weight as it initially does. Researchers have been investigating potential mechanisms of resistance and identify possible biological markers for response after disease progression. Much of the available data is retrospective; however, few randomized clinical trials were recently published and few more are ongoing, addressing this point. In this paper, we intend to review the available published studies investigating the potential role for keeping CDK4/6 inhibitors in play beyond disease progression.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer
    Hecht, Keith A.
    Selby, Christopher
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 195 - 203
  • [2] Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced oestrogen receptor-positive breast cancer
    Dubianski, Roman
    Jagiello-Gruszfeld, Agnieszka
    Nowecki, Zbigniew
    ONCOLOGY IN CLINICAL PRACTICE, 2016, 12 (06): : 209 - 214
  • [3] Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer
    Alvarez, Alvaro
    Bernal, Ana M. M.
    Anampa, Jesus
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 198 (01) : 75 - 88
  • [4] Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer
    Alvaro Alvarez
    Ana M. Bernal
    Jesus Anampa
    Breast Cancer Research and Treatment, 2023, 198 : 75 - 88
  • [5] Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer A Review
    O'Sullivan, Ciara Catherine
    Clarke, Robert
    Goetz, Matthew Philip
    Robertson, John
    JAMA ONCOLOGY, 2023, 9 (09) : 1273 - 1282
  • [6] Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
    Ma, Jun
    Chan, Jack Junjie
    Toh, Ching Han
    Yap, Yoon-Sim
    NPJ BREAST CANCER, 2023, 9 (01)
  • [7] Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
    Jun Ma
    Jack Junjie Chan
    Ching Han Toh
    Yoon-Sim Yap
    npj Breast Cancer, 9
  • [8] Cyclin-Dependent Kinase 4/6 Inhibition in the Treatment of Hormone Receptor-Positive Breast Cancer
    Rugo, Hope S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (10) : 555 - 558
  • [9] Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery
    Houvenaeghel, Gilles
    Classe, Jean-Marc
    Chauvet, Marie-Pierre
    Colombo, Pierre-Emmanuel
    Jouve, Eva
    Reyal, Fabien
    Darai, Emile
    Rouzier, Roman
    Faure-Virelizier, Christelle
    Gimbergues, Pierre
    Coutant, Charles
    Mazouni, Chafika
    Azuar, Anne-Sophie
    Martino, Marc
    Bouteille, Catherine
    Cohen, Monique
    de Nonneville, Alexandre
    CANCERS, 2024, 16 (19)
  • [10] Selective Cyclin-Dependent Kinase 4/6 Inhibitors as Anticancer Drugs: Moving beyond Hormone Receptor-Positive Breast Cancer
    Chaudhuri, Tamojit
    Babu, K. Govind
    Lakshmaiah, K. C.
    Dasappa, Lokanatha
    Jacob, Linu Abraham
    Babu, M. C. Suresh
    Rudresha, A. H.
    Lokesh, K. N.
    Rajeev, L. K.
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (01) : 15 - 20